Table 1. Baseline Characteristics of Patients With Symptomatic Lower Extremity Peripheral Artery Disease (LE-PAD) Within the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
| Characteristic | Patients, No. (%) | |||
|---|---|---|---|---|
| Overall | Rivaroxaban, 2.5 mg, twice a day, plus aspirin, 100 mg, once a day | Rivaroxaban, 5 mg, twice a day | Aspirin, 100 mg, once a day | |
| Randomized, No. | 4129 | 1409 | 1361 | 1359 |
| Age, mean (SD), y | 66.8 (8.8) | 67.1 (8.7) | 66.5 (8.8) | 66.7 (8.8) |
| Male | 2932 (71.0) | 995 (70.6) | 977 (71.8) | 960 (70.6) |
| Currently smoking | 1318 (31.9) | 421 (29.9) | 455 (33.4) | 442 (32.5) |
| History | ||||
| Diabetes | 1940 (47.0) | 664 (47.1) | 632 (46.4) | 644 (47.4) |
| Heart failure | 686 (16.6) | 232 (16.5) | 228 (16.8) | 226 (16.6) |
| Kidney insufficiency at baselinea | 1112 (26.9) | 383 (27.2) | 358 (26.3) | 371 (27.3) |
| High-risk comorbidity | 3481 (84.3) | 1205 (85.5) | 1133 (83.2) | 1143 (84.1) |
| ≥2 Vascular beds affected | 2335 (56.6) | 810 (57.5) | 764 (56.1) | 761 (56.0) |
| Coronary artery disease | 2212 (53.6) | 773 (54.9) | 714 (52.5) | 725 (53.4) |
| Cerebrovascular disease | 214 (5.2) | 69 (0.9) | 80 (5.9) | 65 (4.7) |
| Ankle-Brachial Index score, mean (SD) | 0.94 (0.2) | 0.95 (0.2) | 0.94 (0.2) | 0.94 (0.21) |
| Type of LE-PAD for inclusion | ||||
| Peripheral artery bypass surgery | 694 (16.8) | 229 (16.3) | 248 (18.2) | 217 (16.0) |
| Peripheral percutaneous angioplasty | 1211 (29.3) | 396 (28.1) | 401 (29.5) | 414 (30.5) |
| Previous peripheral artery revascularization or surgery | 1729 (41.9) | 576 (40.9) | 590 (43.4) | 563 (41.4) |
| Limb or foot amputation | 316 (7.7) | 111 (7.9) | 102 (7.5) | 103 (7.6) |
| Intermittent claudication | 2966 (71.8) | 1009 (71.6) | 981 (72.1) | 976 (71.8) |
| Fontaine classification | ||||
| IIa | 1740 (42.1) | 596 (42.3) | 565 (41.5) | 579 (42.6) |
| IIb | 1107 (26.8) | 389 (27.6) | 354 (26.0) | 364 (26.8) |
| III | 164 (4.0) | 47 (3.3) | 73 (5.4) | 44 (3.2) |
| IV | 41 (1.0) | 16 (1.1) | 13 (1.0) | 12 (0.9) |
| Use of angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker | 2780 (67.3) | 928 (65.9) | 932 (68.5) | 920 (67.7) |
| Use of lipid-lowering agent | 3248 (78.7) | 1124 (79.8) | 1073 (78.8) | 1051 (77.3) |
a
Defined as an estimated glomerular filtration rate less than 60 mL/min.